Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 9 March 2022, 15:06 HKT/SGT
Share:
    

Source: Eisai
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)

TOKYO, Mar 9, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.

Under the Certified Health and Productivity Management Outstanding Organization Recognition Program, the Nippon Kenko Kaigi examines large enterprises, small and medium enterprises and other organizations engaging in initiatives for overcoming health-related challenges in regional communities or for promoting health-conscious activities led by the Nippon Kenko Kaigi. It recognizes outstanding enterprises engaging in efforts for health and productivity management by evaluating from a business-management perspective based on following criteria: "management philosophy and policies", "organized frameworks", "systems and implementation of measures", and "evaluation and improvement". Eisai exceeded the average of its industry peers in all criteria, receiving particularly high scores for such as the "information disclosure and dissemination to other companies" (in the criteria of management philosophy and policies), "well adopted by employees" (in the criteria of organized frameworks), "lifestyle improvement" and "other measures*" (in the criteria of systems and implementation of measures). The program was launched in 2017, and this is the fourth time that Eisai was certified as a "White 500" company.

Eisai issued the "Eisai Health Declaration" in 2019, and has strategically implemented health management for employees from a management perspective.

Eisai will continue to promote its efforts toward practicing the health and productivity management and to further contribute to increasing the benefits of patients and their families.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides. Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word.

Eisai regards its employees as an important stakeholder and asset for the realization of its hhc philosophy.

Eisai believes that its commitment to maintaining and improving the health of human resources is fundamental to develop highly engaged employees who are motivated to contribute voluntarily toward the realization of the hhc philosophy.

*Measures to address health issues specific to women and the elderly, long working hours, mental health, dependents of the company's employees, and prevention of infectious disease during COVID-19 pandemic.

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
May 21, 2026 23:23 HKT/SGT
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
Apr 21, 2026 19:52 HKT/SGT
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Mar 27, 2026 19:14 HKT/SGT
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Mar 27, 2026 17:19 HKT/SGT
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Mar 23, 2026 10:19 HKT/SGT
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Mar 19, 2026 09:54 HKT/SGT
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 17, 2026 18:49 HKT/SGT
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
Mar 12, 2026 16:21 HKT/SGT
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Mar 11, 2026 11:07 HKT/SGT
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 2, 2026 08:49 HKT/SGT
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: